HomeCompareCTBO vs EPRT

CTBO vs EPRT: Dividend Comparison 2026

CTBO yields 198.02% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CTBO wins by $112.63M in total portfolio value
10 years
CTBO
CTBO
● Live price
198.02%
Share price
$1.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$112.70M
Annual income
$56,534,499.65
Full CTBO calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — CTBO vs EPRT

📍 CTBO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCTBOEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CTBO + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CTBO pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CTBO
Annual income on $10K today (after 15% tax)
$16,831.68/yr
After 10yr DRIP, annual income (after tax)
$48,054,324.70/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, CTBO beats the other by $48,043,410.08/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CTBO + EPRT for your $10,000?

CTBO: 50%EPRT: 50%
100% EPRT50/50100% CTBO
Portfolio after 10yr
$56.38M
Annual income
$28,273,670.18/yr
Blended yield
50.15%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

CTBO
No analyst data
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CTBO buys
0
EPRT buys
0
No recent congressional trades found for CTBO or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCTBOEPRT
Forward yield198.02%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$112.70M$63.4K
Annual income after 10y$56,534,499.65$12,840.73
Total dividends collected$106.15M$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: CTBO vs EPRT ($10,000, DRIP)

YearCTBO PortfolioCTBO Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$30,502$19,801.98$11,205$505.18+$19.3KCTBO
2$89,086$56,448.56$12,672$682.46+$76.4KCTBO
3$249,403$154,080.96$14,490$930.48+$234.9KCTBO
4$670,003$403,142.26$16,786$1,282.69+$653.2KCTBO
5$1,729,066$1,012,162.66$19,753$1,791.56+$1.71MCTBO
6$4,291,289$2,441,188.37$23,677$2,541.64+$4.27MCTBO
7$10,253,990$5,662,310.92$29,008$3,672.99+$10.22MCTBO
8$23,616,660$12,644,890.45$36,463$5,425.08+$23.58MCTBO
9$52,487,868$27,218,041.68$47,238$8,221.57+$52.44MCTBO
10$112,696,518$56,534,499.65$63,385$12,840.73+$112.63MCTBO

CTBO vs EPRT: Complete Analysis 2026

CTBOStock

Cantabio Pharmaceuticals, Inc., a preclinical stage biotechnology company, focuses on the research, development, and commercialization of novel therapies for Parkinson's disease (PD), Alzheimer's disease (AD), and other related diseases. Its lead programs include CB101, a DJ-1 targeting small molecule pharmacological chaperone for use in the treatment of PD; CB201, a CNS penetrant engineered DJ-1 protein for use in the treatment of PD; CB301, a Tau protein targeting small molecule pharmacological chaperone for use in the treatment of AD; and CB401, an Aß targeting small molecule pharmacological chaperone for use in the treatment of AD. The company has a collaboration agreement with Luxembourg Institute of Health to research the therapeutic targeting of the DJ-1 - protein to treat immune associated diseases. The company was founded in 2009 and is based in Palo Alto, California.

Full CTBO Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this CTBO vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CTBO vs SCHDCTBO vs JEPICTBO vs OCTBO vs KOCTBO vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.